Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2636771 + Paclitaxel in Advanced Gastric Adenocarcinoma
NCT02615730Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Feb 2016
- Primary completion
- Mar 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GSK-2636771 in gastric adenocarcinoma, sponsored by Yonsei University. Primary endpoints: Recommended Phase II Dose at 4 weeks and Progression-Free Survival at 6 weeks. Started Feb 2016; status: completed.
02
Drugs
GSK-2636771
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT02615730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02615730.